Meet The Company Giving Patients Access To Unlicensed Medicines
This article was originally published in Scrip
There is a big unmet need around the ethical management and supply of unlicensed medicines. Their unlicensed status could be due to the products still being experimental, or that the products have been approved in certain territories but not others. And as patients and their physicians become increasingly demanding about access to hard-to-get medicines, a trend which is expected to continue, pharma companies understand they have a responsibility to work with physicians to enable access. And companies such as Clinigen are there to help. Scrip spoke to Clinigen's deputy CEO Shaun Chilton.